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DObjectives: Chronic thromboembolic pulmonary hypertension can be cured by pulmonary endarterectomy.
Operability assessment remains a major concern, because there are nowell-defined criteria to discriminate prox-
imal from distal obstructions, and surgical candidacy depends mostly on the surgeon’s experience. The intrao-
perative classification of chronic thromboembolic pulmonary hypertension describes 4 types of lesions, based on
anatomy and location. We describe our recent experience with the more distal (type 3) disease.
Methods:More than 500 pulmonary endarterectomies were performed at Foundation I.R.C.C.S. Policlinico San
Matteo (Pavia, Italy). Because of recent changes in the patient population, 331 endarterectomies performed from
January 2008 to December 2013 were analyzed. Two groups of patients were identified according to the intra-
operative classification: proximal (type 1 and type 2 lesions, 221 patients) and distal (type 3 lesions, 110 pa-
tients).
Results: The number of endarterectomies for distal chronic thromboembolic pulmonary hypertension increased
significantly over time (currently 37%). Deep venous thrombosis was confirmed as a risk factor for proximal
disease, whereas patients with distal obstruction had a higher prevalence of indwelling intravascular devices.
Overall hospital mortality was 6.9%, with no difference in the 2 groups. Postoperative survival was excellent.
In all patients, surgery was followed by a significant and sustained improvement in hemodynamic, echocardio-
graphic, and functional parameters, with no difference between proximal and distal cases.
Conclusions: Although distal chronic thromboembolic pulmonary hypertension represents the most chal-
lenging situation, the postoperative outcomes of both proximal and distal cases are excellent. The diagnosis
of inoperable chronic thromboembolic pulmonary hypertension should be achieved only in experienced
centers, because many patients who have been deemed inoperable might benefit from favorable surgical out-
comes. (J Thorac Cardiovasc Surg 2014;148:1005-12)Supplemental material is available online.e Department of Clinical-Surgical, Diagnostic and Pediatric Sciences,a Uni-
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The Journal of Thoracic and CarChronic thromboembolic pulmonary hypertension
(CTEPH) can be cured in most patients with pulmonary
endarterectomy (PEA).1-9 Because there are no well-
defined criteria to discriminate surgically accessible from
inaccessible obstructive lesions, the operability assessment
relies only on the surgeon’s decision.10,11 Despite growing
experience worldwide, and although currently available
tools are adequate in identifying the presence of
pulmonary arterial obstruction at a distal level, the criteria
for operability remain variable and center-dependent.3
Because a significant proportion of patients with CTEPH
may be deemed inoperable over concerns of distal and sur-
gically inaccessible disease, patients should not be consid-
ered inoperable unless they have been evaluated by an
experienced surgeon.1
Assessment of the severity of pulmonary hypertension in
relation to the location of arterial obstructions is essential
for surgical candidacy. An excessive increase in pulmonary
vascular resistance (PVR) alone, usually greater than 1000
to 1200 dyn$s$cm5 in the reported series,3,4,12 should not
be considered a contraindication to PEA, because patients
will benefit from surgery performed by an experienced
surgeon.11 Because persistent pulmonary hypertension isdiovascular Surgery c Volume 148, Number 3 1005
Abbreviations and Acronyms
CI ¼ confidence interval
CTEPH ¼ chronic thromboembolic pulmonary
hypertension
PEA ¼ pulmonary endarterectomy
PVR ¼ pulmonary vascular resistance
WHO ¼World Health Organization
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Done of the most important determinants of surgical
outcome,4,13 the preoperative identification of patients
with severe CTEPH and little thromboembolic lesions
with concomitant small-vessel disease is crucial. Several
techniques are being studied to attempt to partition the up-
stream from downstream pulmonary resistance, but they
remain investigational.14,15
The current article shows the outcome of patients with
distal CTEPH undergoing PEA at a single experienced
center in a recent series, emphasizing the efficacy of the
developed operative technique that allows resection of
thromboembolic lesions at a subsegmental level with
excellent results.
METHODS
Patient Selection
From April 11, 1994, to March 31, 2014, 546 consecutive patients diag-
nosed with CTEPH underwent PEA. A prospective database, approved by
the institutional review board, records patients’ information. All patients
provided informed consent. Except for urgent or emergency operations,
all patients with CTEPH admitted to Foundation I.R.C.C.S. Policlinico
SanMatteo (Pavia, Italy) underwent a complete diagnostic workup accord-
ing to our published standardized protocol.16,17 From 2005 onward, the
operability assessment was performed by the same surgeon.
Underlying severe parenchymal lung disease is the only contraindica-
tion to PEA at Foundation I.R.C.C.S. Policlinico SanMatteo. Some authors
also consider the severity of hemodynamic impairment, associated medical
conditions, and patient age.3,18 During the last 5 years, only 7 patients were
excluded from surgery on the basis of only age and preoperative conditions,
compared with 322 PEAs performed.
Regardless of preoperative findings, pulmonary arteries are always
explored bilaterally during surgery, because imaging tools may fail to detect
partially obstructed or recanalized arteries or intraluminal webs, which are
almost regularly perfused by contrast agent. With the emerging evidence
that some unexpected distal arterial obstructions could be successfully
removed intraoperatively, the line between accessible and inaccessible
lesions has been pushedmore distally over time, contributing to the learning
curve of the center. During theyear 2013, 99 patientswithCTEPHwere eval-
uated and 92 patients were deemed operable, for an operability rate of 93%.
At Foundation I.R.C.C.S. Policlinico SanMatteo, 331 consecutive PEAs
were performed from January 1, 2008, to December 31, 2013. Two groups
of patients were identified according to the intraoperative Jamieson’s clas-
sification10: proximal (type 1 and type 2 lesions, 221 patients) and distal
(type 3 lesions, 110 patients). Four patients with intraoperative type 4
CTEPH were excluded from the analysis; 2 patients underwent successful
rescue heart-lung transplantation, and they are still alive at 49-month and
8-month follow-ups; 1 patient was successfully weaned from cardiopulmo-
nary bypass and is doing well on combination therapy with 2 specific
pulmonary vasodilator agents; and 1 patient was not listed for transplanta-
tion because of absolute contraindication and died early postoperatively.1006 The Journal of Thoracic and Cardiovascular SurSurgical Technique
A permanent inferior vena cava filter is placed the day before surgery,
unless contraindicated. In 34 patients (10.3%), the device was not placed
because of the following contraindications: metal allergy (17), inferior
vena cava abnormality (6) or complete thrombosis (4), presence of intra-
vascular catheters as a trigger for microembolism (6), and thalassemia (1).
The surgical approach is carried out according to the published surgical
technique,19 except for some technical details described previously.9 From
2007 onward, a combination of multiple short (7-10 minutes) intermittent
sessions of circulatory arrest with moderate hypothermia (24C), interrup-
ted by adequate (5-minute) periods of reperfusion driven by continuous
near-infrared spectroscopy monitoring, represents the procedure of
choice.20 In our experience, despite long cumulative circulatory arrest
times, this alternative cardiopulmonary bypass management was safe and
associated with an increased rate of uncomplicated recovery, with a trend
toward reduced neurologic events. Given the extra dissection time that al-
lowed more distal disease to be cleared, the operability rate could be
extended. By reducing the burden of deep hypothermia, this technique
could be an effective alternative to the original technique in case of distal
disease in particularly frail patients, including the elderly.
Norepinephrine and dobutamine (or epinephrine) are routinely adminis-
tered to assist weaning from cardiopulmonary bypass by improving the sys-
temic perfusion pressure, including coronary blood flow. When indicated,
inhaled nitric oxide is administered to improve right ventricular function,
notably if PVR is not yet back to normal.
After PEA, the cardiac output is generally high because of the remark-
able unloading of the hypertrophic right ventricle and may lead to lung re-
perfusion edema. Thus, inotropes and inhaled nitric oxide are rapidly
discontinued, vasopressor agents are continued for a few days, and a
vigorous diuresis is achieved to obtain negative fluid balance. A protective
ventilation (high positive end-expiratory pressure and low tidal volume) is
preferred to prevent both lung reperfusion edema and ventilation-induced
lung injury. Extubation is performed as soon as possible, switching to hel-
met continuous positive airways pressure ventilation usually for a few days.
Statistical Analysis
Data are presented as mean and standard deviation and 95% confidence
interval (CI) or median and 25th to 75th percentiles, if continuous, and
counts and percent, if categoric; comparison between groups was per-
formed with the Student t test or Mann–WhitneyU test and the Fisher exact
test, respectively. Log transformation was used when indicated. The asso-
ciation of intraoperative classification and postoperative acute events was
assessed with Fisher exact test; the risk difference (95% CI) and the risk
ratio (95% CI) were computed.
Survival was plotted according to the Kaplan–Meier method and
compared between groups with the log-rank test. Mortality per 100
person-years was computed. Hazard ratios (95% CI) were derived from
the Cox model. Generalized linear models with identity or logit link with
Huber–White robust standard errors (to account for within-patient correla-
tion of measures) were fitted to compare the clinical, functional, and hemo-
dynamic outcomes over time between groups.
The comparison of the time profile for each group relied on a Wald test
of interaction of group and treatment. Because of the low number of events,
no multivariable analysis for hospital and follow-upmortality could be per-
formed. Stata 12.1 (StataCorp LP, College Station, Tex) was used for
computation. All tests were 2-sided. Bonferroni correction was used for
post hoc comparisons.
RESULTS
Because of the learning curve, the number of PEA oper-
ations in patients with type 3 CTEPH increased signifi-
cantly over a 6-year period (P ¼ .035, Fisher exact test),
as shown in Figure E1.gery c September 2014
TABLE 1. Preoperative concomitant diseases, underlying medical conditions, and presenting characteristics
Proximal Distal
P valueN ¼ 221 N ¼ 110
Preoperative concomitant diseases and underlying medical conditions
Age (y) 61  15 (59-63) 60  14 (58-63) .578
Female (n) 119 (53.8) 74 (67.3) .024
LOD (y) 2 (1-5) 2 (1-5) .851
BMI (kg/m2) 26  5 (26-27) 25  5 (24-26) .095
BMI<22 kg/m2 (n) 41 (18.6) 33 (30.0) .025
BMI 30 kg/m2 (n) 43 (19.5) 22 (20.0) 1.000
Smokers (n) 19 (8.6) 8 (7.3) .788
Previous DVT (n) 134 (60.6) 42 (38.2) <.001
Intravascular devices (n) 8 (3.6) 11 (10.0) .024
Splenectomy (n) 4 (1.8) 4 (3.6) .448
Blood groups non-0 (n) 168 (76.0) 74 (67.3) .114
Oxygen supply (n) 112 (50.7) 49 (44.6) .297
Urgent/emergency (n) 28 (12.7) 7 (6.4) .217
Medication for PAH (n) 38 (17.2) 33 (30.0) .010
Systemic arterial hypertension (n) 88 (39.8) 39 (35.5) .473
Dyslipidemia (n) 58 (26.2) 25 (22.7) .505
Diabetes (n) 12 (5.4) 4 (3.6) .593
Coronary artery disease (n) 15 (6.8) 12 (10.9) .386
Chronic obliterative arterial disease (n) 4 (1.8) 2 (1.8) 1.000
Atrial fibrillation (n) 21 (9.5) 3 (2.7) .058
Chronic renal failure (n) 16 (7.2) 6 (5.5) .644
History of cancer (n) 21 (9.5) 10 (9.1) 1.000
Neurologic disorders (n) 17 (7.7) 8 (7.3) .627
Presenting characteristics
mPAP (mm Hg) 44  10 (43-46) 46  10 (44-48) .153
PVR (dyne$s$cm5) 876  392 (823-929) 926  337 (862-989) .236
CO (L/min) 3.9  1.3 (3.7-4.1) 3.7  1.2 (3.5-4.0) .315
CI (L/min/m2) 2.1  0.6 (2.0-2.2) 2.2  0.6 (2.0-2.3) .526
BNP (pg/mL) 189 (61-459) 188 (68-396) .571
NT-proBNP (pg/mL) 1382 (392-3192) 1290 (444-2279) .225
TAPSE (mm) 17  4 (16-18) 17  4 (16-18) .901
Moderate-to-severe TR (n) 146 (66.4) 75 (68.2) .804
PAO2 (mm Hg) 65  12 (64-67) 66  11 (64-68) .773
WHO class (II/III/IV) (%) 12/53/35 15/54/31 .597
Modified Bruce exercise test (m) 51 (0-143) 52 (0-102) .738
6-min walking distance (m) 277  118 (261-294) 289  112 (267-310) .424
Bold values indicate significance (P<.05). BMI, Body mass index; BNP, B-type natriuretic peptide; CI, cardiac index; CO, cardiac output; DVT, deep venous thrombosis; LOD,
length of the disease; mPAP, mean pulmonary arterial pressure; NT-proBNP, N-terminal prohormone of BNP; PAH, pulmonary arterial hypertension; PAO2, partial pressure of ox-
ygen in arterial blood; PVR, pulmonary vascular resistance; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation;WHO, World Health Organization.
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groups (Table 1). Distal cases were predominantly female,
with a higher incidence of being underweight. The preva-
lence of deep venous thrombosis was higher in proximal
cases, whereas distal cases had a higher prevalence of
indwelling intravascular devices, such as central venous
catheters, pacemakers, and ventriculoatrial shunt. No differ-
ence was observed regarding the age at operation, the smok-
ing status, the need for oxygen supply, and the prevalence of
splenectomy and blood groups non-0. The length of the dis-
ease, defined as the time between the onset of symptoms
and the surgery, revealed a late referral for both proximal
and distal cases. Urgent PEA was defined as the need forThe Journal of Thoracic and Carsurgery within 48 hours of the admission. Emergency
PEA was defined as the need to bring the patient immedi-
ately to the operating room because of severe hemodynamic
instability. No significant difference was found regarding
the need for urgent or emergency PEA between the 2
groups, despite a trend toward more emergency and urgent
operations in proximal cases. Distal cases received preoper-
ative medication more frequently, with specific drugs for
pulmonary arterial hypertension, and combination therapy
was more common (13/33) compared with proximal cases
(4/38). No significant difference was observed in terms of
medical history, concomitant diseases, and underlying
medical conditions. Only atrial fibrillation was found todiovascular Surgery c Volume 148, Number 3 1007
TABLE 2. Intraoperative comparison and early postoperative
outcome
Proximal Distal
P
value
Bilateral PEA (n) 192 (86.9) 95 (86.4) 1.000
Associated
procedures (n)
38 (17.2) 19 (17.3) 1.000
Total CPB time
(min)
338  81 (327-348) 361  64 (349-373) .005
Hypothermia (C) 24.0  0.9 (23.9-24.1) 23.7  1.0 (23.5-23.8) .003
Total HCA time
(min)
84  32 (80-89) 102  28 (97-107) <.001
PAO2/FIO2 6 h 284  91 (271-296) 280  112 (259-301) .758
MV duration (d) 2 (1-3) 2 (1-4) .565
ICU stay (d) 4 (3-7) 4 (3-8) .962
Postoperative
hospital stay (d)
13 (10-16) 13 (11-17) .541
Risk
Risk difference
P value(95% CI)
Univariate analysis
Hospital mortality 1.8 (4.2 to 7.9) .647
Proximal 6.3%
Distal 8.1%
Lung reperfusion edema 0.5 (4.4 to 3.4) 1.000
Proximal 3.2%
Distal 2.7%
Tracheostomy 1.9 (7.8 to 3.9) .662
Proximal 8.3%
Distal 6.4%
Neurologic event 4.7 (10.6 to 1.1) .209
Proximal 10.2%
transient 13/22
permanent 9/22
Distal 5.5%
transient 5/6
permanent 1/6
Bold values indicate significance (P<.05). CI, Confidence interval; CPB, cardiopul-
monary bypass; HCA, hypothermic circulatory arrest; ICU, intensive care unit; MV,
mechanical ventilation; PAO2/FIO2 6 h, partial pressure of oxygen in arterial blood/
fraction of inspired oxygen ratio 6 hours after admission to ICU; PEA, pulmonary
endarterectomy.
TABLE 3. Hemodynamic time course after pulmonary
endarterectomy
Proximal Distal
Mean pulmonary arterial pressure (mm Hg)
Preoperative 44  10 46  11
At discharge 22  7 24  6
3-mo follow-up 24  9 25  7
12-mo follow-up 23  7 24  8
P value* <.001 <.001
PVR (dyne$s$cm5)
Preoperative 876  392 926  337
At discharge 251  146 295  161
3-mo follow-up 270  175 300  139
12-mo follow-up 243  115 300  224
P value* <.001 <.001
Cardiac output (L/min)
Preoperative 3.9  1.3 3.7  1.2
At discharge 5.0  1.2 4.7  1.2
3-mo follow-up 5.2  1.1 5.0  1.2
12-mo follow-up 5.0  1.1 4.7  1.0
P value* <.001 <.001
PVR, Pulmonary vascular resistance. *Each time point versus preoperative. Test of
interaction: P ¼ .975 (mean pulmonary arterial pressure); P ¼ .777 (PVR);
P ¼ .825 (cardiac output).
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nonsignificance.
The analysis of all the hemodynamic, echocardiographic,
and functional parameters, as well as the biomarkers
explored, showed no significant difference between prox-
imal and distal cases (Table 1). All the patients presented
with severe pulmonary arterial hypertension and low car-
diac output, resulting in right heart failure and reduced ex-
ercise tolerance.
Bilateral PEA was performed in approximately 87% of
patients, with no difference in the 2 groups (Table 2). The
following associated cardiac procedures were performed:
27 patent foramen ovale closures, 17 coronary artery
surgeries, 5 aortic or mitral valve surgeries, 8 parenchymal
lung surgeries, and 4 right atrial or ventricular1008 The Journal of Thoracic and Cardiovascular Surthrombectomies. Both the total cardiopulmonary bypass
time and the total circulatory arrest time were significantly
longer in distal cases because of the need for extra dissec-
tion time. During PEA in distal cases, the level of hypother-
mia was slightly but significantly lower.
Good postoperative respiratory function was observed in
both groups, with no difference in terms of partial pressure
of oxygen in arterial blood/fraction of inspired oxygen ratio
6 hours after admission to the intensive care unit. All pa-
tients experienced similar mechanical ventilation duration,
intensive care unit stay, and total postoperative hospital stay
after surgery (Table 2). Overall hospital mortality was
6.9%, with no difference in the 2 groups. The main causes
of hospital mortality were airway bleeding (7/23, 30%),
persistent pulmonary hypertension (5/23, 22%), lung infec-
tions (5/23, 22%), and irreversible right heart failure (2/23,
9%). No differencewas observed at univariate analysis with
regard to the risk of developing lung reperfusion edema, the
need for tracheostomy, and the risk of experiencing neuro-
logical events, mostly transient. Hemodynamic improve-
ment after surgery was significant and sustained in both
groups (Table 3), with normalization of mean pulmonary
arterial pressure and PVR.
Postoperative follow-up after discharge was complete for
297 patients (96.4%), with a median time of 31 (13-49)
months and a total time of 9758 months. Postoperative sur-
vival was excellent in both groups (Figure 1), with no signif-
icant difference (P ¼ .429) and a hazard ratio for mortality
of 0.72 (0.32-1.62) at Cox model. Mortality rate was 4.13%
(2.74%-6.21%) per year and 3.13% (1.56%-6.25%) per
year for proximal and distal cases, respectively.gery c September 2014
FIGURE 1. Survival after PEA.
TABLE 4. Partial pressure of oxygen in arterial blood, modified Bruce
exercise test, and 6-minute walking distance time course after
pulmonary endarterectomy
Proximal Distal
Arterial partial pressure of oxygen (mm Hg)
Preoperative 65  12 66  11
3-mo follow-up 82  13 80  11
12-mo follow-up 80  11 80  11
P value* <.001 <.001
Modified Bruce exercise test (m)
Preoperative 51 (0-143) 52 (0-102)
3-mo follow-up 495 (182-658) 435 (143-586)
12-mo follow-up 520 (261-709) 474 (225-620)
P value* <.001 <.001
6-min walking distance (m)
Preoperative 277  118 289  112
3-mo follow-up 391  118 398  107
12-mo follow-up 389  118 396  112
P value* <.001 <.001
*Each time point versus preoperative. Test of interaction: P¼ .317 (partial pressure of
oxygen in arterial blood); P ¼ .205 (modified Bruce exercise test); P ¼ .962 (6-min
walking distance).
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inWorld Health Organization (WHO) functional class early
after PEA. Three months after surgery, 99% of patients
were in WHO class I or II. In all patients, surgery was fol-
lowed by a significant and sustained improvement in hemo-
dynamic, echocardiographic, biochemical, and functional
parameters, with no difference between proximal and distal
cases. Data are shown in Tables 3, 4, and E1, and Figure E2.
Comparison of time profiles between groups was assessed
with test of interaction.
DISCUSSION
The main result of the present study is that PEA is a safe
and effective operation in patients presenting with distal
CTEPH, which is the most challenging situation. Because
of the lack of regulation by the National Regulatory Author-
ity, there is poor standardization of the diagnostic workup
and treatment protocol for CTEPH, resulting in a wide va-
riety of referral patterns. This causes frequent misdiagnosis
and late diagnosis, leading to excessive delay in patient re-
ferrals, as shown by the excessive length of the disease and
the high proportion of patients presenting preoperatively
with WHO functional class IV symptoms.
As previously reported,5,21 there is a significant
proportion of patients with operable CTEPH receiving
pulmonary vasodilators agents preoperatively, contributing
to the delay in patient referrals. This is significantly more
frequent in cases of distal CTEPH, partially because of
frequent misdiagnosis in this difficult subset of patients.
Of note, 7 patients with distal CTEPH underwent PEA
after having been enrolled in randomized clinical trials
(Bosentan Effects in Inoperable Forms of Chronic
Thromboembolic Pulmonary Hypertension [BENEFIT]
trial, 2 patients, and Chronic Thomboembolic Pulmonary
Hypertension Soluble Guanylate Cyclase-Stimulator Trial-
1 [CHEST-1] trial, 5 patients) with specific drugs for inoper-
able CTEPH and whose inoperability was confirmed by an
external, international, dedicated committee of experienced
surgeons. Because of the surgeon’s learning curve, theseThe Journal of Thoracic and Carpatients were deemed operable approximately 2 years after
the first assessment, despite the unchanged extent of
thromboembolic obstructions. After surgery, these patients
experienced a significant hemodynamic improvement (pre-
operative PVR 1112  367 dyne$s$cm5, postoperative
PVR 312  121 dyne$s$cm5, P<.001). Unlike what has
been reported anecdotally by some experienced surgeons,
the preoperative use of these agents did not affect opera-
bility, because neither inflammation nor destruction of the
arterial tissue planes was noticed at operation.
The operability assessment in CTEPH remains an issue.
Although proximal organized lesions represent the ideal sit-
uation, preoperative imaging often tends to underestimate
the amount of thromboembolic lesions, especially in pa-
tients with type 3 lesions. Lung ventilation/perfusion scan
is still the most sensitive test (>96%) for the diagnosis of
CTEPH.22 With an abnormal lung scan result, the next im-
aging step is computed tomography for disease confirma-
tion and operability assessment. Despite advances in
computed tomography, pulmonary angiography still holds
a key role especially in patients with distal lesions, mainly
because of the dynamic representation of the pulmonary cir-
culation at the subsegmental level.
Patients with distal CTEPH were predominantly female,
with a significant proportion being underweight. This condi-
tion might have contributed to the more distal location of
small thromboemboli. Previous deep venous thrombosis
has been confirmed as an important risk factor for proximal
CTEPH, whereas the presence of indwelling intravascular
devices seems to increase the risk of developing CTEPH
with more distal thromboembolic obstructions. No
difference was observed in the 2 groups with regard to
other recognized risk factors for the development ofdiovascular Surgery c Volume 148, Number 3 1009
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tory of cancer.23-25 Despite borderline nonsignificance,
preoperative atrial fibrillation was present more frequently
among proximal cases, probably because of the impact of
the higher upstream pressure15 on right heart function in
proximal CTEPH.
All of the hemodynamic, laboratory, echocardiographic,
and functional parameters explored showed severe CTEPH
in both groups, causing significant right heart failure and
reduced functional capacity, regardless of disease location.
By using our alternative cardiopulmonary bypass strategy,
PEA was performed safely in distal cases despite long cu-
mulative circulatory arrest times, and the extra dissection
time allowed more distal disease to be cleared effectively.
Although type 3 CTEPH represents the most challenging
situation, the surgical outcomes of proximal and distal cases
were similar. Of note, the incidence of postoperative lung
reperfusion edema was low, unlike what is reported in the
literature even in most experienced centers.3,20
Although a complete recovery was shown in both groups
of patients after successful operations, a subset of 15 patients
(proximal disease in 14, distal disease in 1) remained with
moderate-to-severe tricuspid regurgitation at 12-month
follow-up, with persistent right ventricle dilation (32  4
mm), likely due to the failure of the right ventricle to
remodel after surgery. No correlation was observed with
the length of the disease. Of these patients, 4 (27%) were
aged more than 70 years at surgery. Only 1 of these patients
remained inWHO functional class III after surgery; all of the
other patients were inWHO class I or II at 12-month follow-
up, with PVR of 335 284 dyne$s$cm5, 6-minutewalking
distance of 373 131m, andmodifiedBruce exercise test of
412  214 m. Five (33%) of these patients were receiving
specific pulmonary vasodilators preoperatively, and 3
patients continued to receive the same drug postoperatively.
None of the other 12 patients were treated with pulmonary
vasodilators postoperatively. A further evaluation with car-
diac magnetic resonance or endomyocardial biopsy could
better characterize this peculiar subset of patients.
No difference was observed with regard to hospital mor-
tality and long-term survival in the 2 groups, confirming
that PEA can be performed safely even in distal CTEPH.
Overall operative mortality is high compared with other
large contemporary series reported by experienced institu-
tions. This could be due to the rate of patients presenting
with WHO class IV symptoms at operation, which is still
high in our experience (112/331, 33.8%), and to the
increasing number of elderly patients (118/331, 35.6%).
No patient has ever been excluded from surgery on the basis
of age and preoperative conditions, because the only contra-
indication to PEA at Foundation I.R.C.C.S. Policlinico San
Matteo is underlying severe parenchymal lung disease.
Moreover, a substantial number of urgent or emergency op-
erations were performed, reflecting the high number of1010 The Journal of Thoracic and Cardiovascular Surpatients presenting in poor clinical conditions, contributing
to increase the overall mortality. A significant cause of oper-
ative mortality was airway bleeding. After the recent intro-
duction of an innovative surgical technique,26 this particular
cause of death has become more rare.
Study Limitations
Any retrospective study is subject to selection bias. The
operation, baseline state, and outcome were obtained from
existing recorded information. However, our study included
all consecutive incident patients. The database was not
modified over time, and all variables were collected pro-
spectively. Case groups were identified from the same pop-
ulation of operated patients with CTEPH, and groups were
contemporaneous. Since 2009, approximately 60 PEAs
have been performed each year. Given the significant in-
crease in the number of PEAs performed, we decided to
consider patients undergoing operation from January 1,
2008, to December 31, 2013, to make the series more homo-
geneous and to avoid possible bias due to the learning curve.
CONCLUSIONS
The aim of this report is to raise the awareness of the fact
that the diagnosis of inoperable CTEPH should be achieved
by an experienced surgeon in an experienced center, because
many patients who have been deemed inoperable might be
operable and could benefit fromexcellent surgical outcomes.
Consideration about the administration of medical therapy
for patients with CTEPH should occur only after surgical
assessment, because currently available drugs are not alter-
natives to PEA.27 Therefore, a second opinion from another
experienced center might be useful before considering the
patient as inoperable. The mere location of thromboembolic
lesions should not deter the referral of patients to experi-
enced centers, because this delay might be associated with
the development of secondary pulmonary arteriopathy, the
progression of pulmonary hypertension, and the irreversible
damage of the obstructed pulmonary arteries,28 resulting in
worsening of surgical candidacy. In experienced centers,
despite the fact that distal CTEPH represents the most
challenging situation, the postoperative outcomes of both
proximal and distal cases are excellent. As an ethical consid-
eration, this becomes particularly meaningful because PEA
should maximize the use of scarce organ donors by offering
a nontransplant option to patients with distal CTEPH.
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DrMichael Madani (La Jolla, Calif). It is a pleasure to see that
CTEPH and PEA are finally getting recognition that they are no
longer obscure diseases and obscure operations that are performed
in a few centers around the world, but still there is a lot of work that
needs to be done and is ahead of us.
As you know, we have performed more than 3000 of these op-
erations at our institutions, and our referrals are increasing and
there are many patients with distal disease, but we believe the dis-
ease is still severely underdiagnosed in the United States and
around the world.
Furthermore, as you pointed out, what is evenmore disturbing is
that patients are not being referred for surgery because of lack of
experience in determining who is and is not operable in so-called
distal disease. Congratulations on showing that even in this patient
population, you can achieve significant hemodynamic improve-
ment and potential cure.
I have 3 questions for you. First, I’m puzzled by your technique
of multiple intermittent circulatory arrest of 5 to 10 minutes, each
of which results in approximately 100 minutes of circulatory arrest
and 6 hours of bypass. Why do you use this technique?
Dr Grazioli. The technique we use consists of moderate hypo-
thermia at 24 degrees, short arrest session from 7 to 10minutes, and
reperfusion periods for more than 5 minutes. We arrived at this last
management with a gradual change. We use this technique for 2
principal reasons: to have more neurologic protection because of
reperfusion periods and monitoring of cerebral blood flow satura-
tion and to allow a longer time for dissection to accurately remove
distal lesions. This technique allows us to explore the segmental
branches that can appear patent at CT scan or angiography.
Dr Madani. I somewhat disagree with that approach, and I
don’t think it’s necessarily superior or equivalent to multiple
studies showing that you can have 1 circulatory arrest time. The
average time is approximately 15 to 20 minutes. You need approx-
imately 5 to 10 minutes just to have the bloodless field when you
get into distal vessels, and there are several studies that have shown
that approach to be safe. My second question relates to that
because in your series, the mortality is still approximately 6.9%.
Is that related to this or are you doing anything to improve on
the mortality overall.
Dr Grazioli.We think the mortality of 7% is the same when we
used the first technique. However, this mortality is high, 7% is
high, and this is due to the late referral of the patients at our center.diovascular Surgery c Volume 148, Number 3 1011
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DWe sometimes have patients with an advanced disease, in func-
tional class IV. For this reason, we try to discern this disease at
another center.
Dr Madani. My last question is related to the incidence of
tricuspid regurgitation. Approximately 20% of patients had mod-
erate or severe tricuspid regurgitation. Do you do anything with
those patients medically or surgically? Twenty percent with mod-
erate to severe disease seemed somewhat high.
Dr Grazioli. Generally we don’t treat tricuspid regurgitation
with surgery because after PEA there is right ventricle remodeling;
consequently, there is an improvement of tricuspid regurgitation.1012 The Journal of Thoracic and Cardiovascular SurWe have performed a study on right ventricle remodeling, and in
this study 70% of patients had moderate or severe regurgitation
before surgery, and after there was a reduction at 16%. Well, we
don’t say exactly the percentage of patients with moderate-severe
tricuspid regurgitation is high after surgery, but the reduction is
significant; however, we will try to improve this.
Dr Jose Pomar (Barcelona, Spain). So it means that you don’t
do tricuspid annuloplasty before?
Dr Grazioli. No.
Dr Pomar. You don’t do it?
Dr Grazioli. No, we don’t.gery c September 2014
FIGURE E1. PEA operations performed by intraoperative Jamieson’s
classification.
FIGURE E2. WHO functional class changes after PEA. P<.001 at each time point versus preoperative. Test of interaction: P ¼ .327. PEA, Pulmonary
endarterectomy; WHO, World Health Organization.
D’Armini et al Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery c Volume 148, Number 3 1012.e1
A
C
D
TABLE E1. Tricuspid regurgitation, B-type natriuretic peptide, and
N-terminal prohormone of B-type natriuretic peptide time course
after pulmonary endarterectomy
Proximal Distal
Moderate/severe tricuspid regurgitation (%)
Preoperative 146 (66.4) 75 (68.2)
3-mo follow-up 23 (16.2) 14 (16.5)
12-mo follow-up 14 (17.3) 1 (2.7)
P value* <.001 <.001
BNP (Log-[pg/mL])
Preoperative 5.1  1.4 5.0  1.3
At discharge 5.5  0.7 5.7  0.7
3-mo follow-up 4.3  0.8 4.1  0.8
12-mo follow-up 4.1  1.0 3.8  0.8
P value* <.001 <.001
N-terminal prohormone of BNP (Log-[pg/mL])
Preoperative 7.0  1.4 6.8  1.4
At discharge 7.0  0.8 7.0  0.7
3-mo follow-up 5.7  1.0 5.5  0.9
12-mo follow-up 5.4  1.0 5.2  0.9
P valuey <.001 <.001
BNP, B-type natriuretic peptide. *Each time point versus preoperative. yEach time
point versus preoperative (except at discharge). Test of interaction: P ¼ .143
(tricuspid regurgitation); P¼ .098 (B-type natriuretic peptide); P¼ .276 (N-terminal
prohormone of B-type natriuretic peptide).
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